Board Member
Kyverna Therapeutics, Inc. (KYTX)Equibles does not estimate personal net worth.
Warner Biddle is recorded as Board Member at Kyverna Therapeutics, Inc. (KYTX) since January 1, 2024 and CEO at Kyverna Therapeutics, Inc. (KYTX). The newest filing on record that lists Warner Biddle as CEO and Board Member at Kyverna Therapeutics, Inc. (KYTX) is dated April 13, 2026. Kyverna Therapeutics, Inc. reported in an 8-K filed September 16, 2024 that Warner Biddle was appointed Class III director, effective September 16, 2024. Kyverna Therapeutics, Inc. reported in an 8-K filed September 16, 2024 that Warner Biddle was appointed Chief Executive Officer, effective September 16, 2024. The proxy statement of Kyverna Therapeutics, Inc. reports total compensation of $1,814,980 for Warner Biddle in fiscal 2025, including a base salary of $625,000. Disclosed compensation is on record for 2 fiscal years. Warner Biddle has spoken on 4 investor events across 1 company, most recently for Kyverna Therapeutics, Inc. on September 24, 2026. Kyverna Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Kyverna Therapeutics, Inc. includes Christi Shaw (Chairman and Board Member), Greg Martini (CFO), Gregory Martini (CFO and Chief Accounting Officer) and 7 others.
“On September 14, 2024, the Board of Directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) appointed Warner Biddle as the Company’s Chief Executive Officer and as a Class III director of the Company, in each case effective September 16, 2024 (the “Effective Date”).”
“On September 14, 2024, the Board of Directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) appointed Warner Biddle as the Company’s Chief Executive Officer and as a Class III director of the Company, in each case effective September 16, 2024 (the “Effective Date”).”
“Today, we are excited to share longer-term durability and safety data for our lead indications that further reinforce Kyberna's leadership in autoimmune CAR T and our near-term potential to deliver the first approved cell therapy in autoimmune disease, in addition to be the first approved treatment for stiff person…”
“Well, at Caverna, we're leading the world in bringing the transformative power and curative potential of cell therapies to autoimmune diseases. We've got a unique car construct and a well-established manufacturing process.”
“Well, at Kyverna, we're really leading the industry, as you know, Derek, bringing these transformative cell therapies to patients and bringing it to them very, very quickly.”
“Here at Caverna, we're excited to share unprecedented data from our neuroimmunology franchise, including the first registrational primary analysis for an autoimmune CAR-T, marking a significant milestone for Caverna and for the field.”
2024-01-01–present
Last confirmed April 13, 2026
Start not stated–present
Last confirmed April 13, 2026
Biotechnology · Healthcare
CEO, Board Member
2024-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Kyverna Therapeutics, Inc. (KYTX) | Chief Executive Officer | $625,000 | $1,814,980 |
| 2024 | Kyverna Therapeutics, Inc. (KYTX) | Chief Executive Officer | $182,292 | $14,992,896 |
